Antibacterial Mechanisms and Drug Development for Gram-Negative Infections

Gram-negative bacteria pose a formidable challenge due to their dual-membrane architecture, which comprises an inner cytoplasmic membrane and an outer membrane enriched with lipopolysaccharide. This outer barrier, together with efflux pumps and restricted porin channels, limits antibiotic penetration. Classical agents such as β-lactams target penicillin-binding proteins to disrupt peptidoglycan assembly, while aminoglycosides inhibit protein synthesis and polymyxins destabilise the outer membrane. Resistance mechanisms include production of β-lactamases that hydrolyse core antibiotic scaffolds, alterations in porin expression, target modification, and activation of efflux systems. In response, drug development has pursued β-lactamase inhibitors, novel non-β-lactam scaffolds, siderophore–antibiotic conjugates and efflux-pump inhibitors. Structural biology and high-throughput screening have facilitated design of agents with enhanced binding to mutated targets. Complementary approaches such as bacteriophage-derived lysins, antimicrobial peptides and adjuvants to restore existing antibiotic activity are under active investigation. Together, these strategies aim to counter multidrug-resistant pathogens including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, with global significance for hospital- and community-acquired infections.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antibacterial Mechanisms and Drug Development for Gram-Negative Infections publication trend

The graph below shows the total number of articles in antibacterial mechanisms and drug development for gram-negative infections across all publications each year (not limited to Nature Index journals).

Technical terms

Gram-negative bacteria: Bacteria characterised by a complex outer membrane containing lipopolysaccharide, contributing to intrinsic antibiotic resistance.

β-lactamase: Enzyme produced by bacteria that hydrolyses and inactivates β-lactam antibiotics.

Penicillin-binding proteins (PBPs): Enzymes involved in the final stages of peptidoglycan synthesis, which are targets of β-lactam antibiotics.

Outer membrane permeability: Property of the Gram-negative cell envelope that restricts passage of molecules, thereby affecting antibiotic uptake.

Monobactams: A class of monocyclic β-lactam antibiotics designed to evade β-lactamase hydrolysis, active against certain Gram-negative pathogens.

DNA gyrase: Bacterial type II topoisomerase that introduces negative supercoils into DNA, essential for replication and a validated antibiotic target.

References

1. Interaction Mode of the Novel Monobactam AIC499 Targeting Penicillin Binding Protein 3 of Gram-Negative Bacteria. Biomolecules (2021).
2. Substituted‐Amidine Functionalized Monocyclic β‐Lactams: Synthesis and In Vitro Antibacterial Profile. Journal of Chemistry (2021).
3. Virtual screening of novel pyridine derivatives as effective inhibitors of DNA gyrase (GyrA) of salmonella typhi. Current Chemistry Letters (2023).